- Thermoresponsive poly(N -C3 glycine)s
-
Ring-opening polymerization of N-substituted glycine N-carboxyanhydrides (NCAs) was applied to prepare a series of well-defined poly(N-C3 glycine)s (C3 = n-propyl, allyl, propargyl, and isopropyl), polypeptoids, with molecular weights in the range of 1.8-6.6 kg mol-1. Poly(N-isopropyl glycine), a previously unreported polypeptoid, could be obtained by bulk polymerization of the corresponding NCA in the melt. The samples were characterized by spectroscopy (NMR and FT-IR), size exclusion chromatography (SEC), and matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy (MALDI-ToF MS). The polymers could be dispersed in water up to 20-40 g L -1; the poly(N-propargyl glycine) was not soluble in water. Turbidity measurements of the three water-soluble polypeptoids illustrated cloud point temperatures dependent on structural and electronic properties of the side chain. The cloud point temperatures were found to increase in the order C3 = n-propyl (15-25 C) allyl (27-54 C) isopropyl (47-58 C). Long-term annealing of the aqueous solution of poly(N-{n-propyl} glycine) and poly(N-allyl glycine) above the cloud point temperature resulted in the formation of crystalline microparticles with melting points of 188-198 and 157-165 C (differential scanning calorimetry, DSC), respectively, and rose bud type morphology (scanning electron microscopy, SEM).
- Robinson, Joshua W.,Secker, Christian,Weidner, Steffen,Schlaad, Helmut
-
-
Read Online
- HIV protease inhibitors
-
The present invention discloses novel isoquinoline carboxamide derivatives which are HIV protease inhibitors or prodrugs thereof, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds are hydroxyethylamine tripeptide mimetics which act as inhibitors of the HIV aspartyl protease, an essential enzyme in the replicative life cycle of HIV. Consequently, the compounds of this invention may be advantageously used in the treatment of HIV infection, either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers such as cytochrome P450 inhibitors.
- -
-
-